Light Chain Bioscience | Novimmune Sa

Light Chain Bioscience | Novimmune Sa company information, Employees & Contact Information

NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.

Company Details

Employees
80
Founded
-
Address
Chemin Du Pré-Fleuri 15, 3ième Étage,switzerland
Phone
41 22 839 71 41
Email
Co****@****une.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Plan-les-Ouates, Genève
Looking for a particular Light Chain Bioscience | Novimmune Sa employee's phone or email?

Light Chain Bioscience | Novimmune Sa Questions

News

Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti‐Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance - Collet-Brose - 2016 - Journal of Immunology Research - Wiley Online Library

Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti‐Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance - Collet-Brose - 2016 - Journal of Immunology Research Wiley Online Library

Sobi picks up Novimmune drug, strengthening pipeline - BioPharma Dive

Sobi picks up Novimmune drug, strengthening pipeline BioPharma Dive

Sobi to buy Novimmune R&D assets, lay off 90 staff - Fierce Biotech

Sobi to buy Novimmune R&D assets, lay off 90 staff Fierce Biotech

Novimmune enters US$195m option deal with TG Therapeutics Inc. - European Biotechnology Magazine

Novimmune enters US$195m option deal with TG Therapeutics Inc. European Biotechnology Magazine

NovImmune raises $21m - - Global Corporate Venturing

NovImmune raises $21m - Global Corporate Venturing

Sobi, Novimmune secure FDA approval for Gamifant to treat HLH - Pharmaceutical Business review -

Sobi, Novimmune secure FDA approval for Gamifant to treat HLH Pharmaceutical Business review -

Roche licenses Novimmune’s anti-TLR4 antibody - European Biotechnology Magazine

Roche licenses Novimmune’s anti-TLR4 antibody European Biotechnology Magazine

Novimmune partners with LegoChem Biosciences - European Biotechnology Magazine

Novimmune partners with LegoChem Biosciences European Biotechnology Magazine

Top Light Chain Bioscience | Novimmune Sa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant